Medtronic’s Extravascular ICD Stops Ventricular Arrhythmias In Pilot Trial

In a 21-patient first in-human pilot trial, Medtronic’s Extravascular Implantable Cardioverter Defibrillator (EV ICD) system successfully terminated induced ventricular arrhythmias in 89.5% of patients and achieved pacing capture in 95% of patients.

FRIDLEY, MN/USA - JUNE 23, 2014: Medtronic corporate headquarters campus. Medtronicis the world's fourth largest medical device company and is a Fortune 500 company. - Image
• Source: shutterstock.com

[Editor's note:Complete historical information on important medical device trial announcements is available from Informa’s Meddevicetracker. For an archive of previous Medtech Insight articles on medtech clinical trials, visit the Clinical Trials page.]

Medtronic PLC is encouraged by the first in-human experience with its substernal Extravascular Implantable Cardioverter Defibrillator (EV ICD).

More from Clinical Trials

More from R&D